Press Releases

Date Title and Summary Additional Formats
Toggle Summary Stereotaxis Announces CFO Transition
ST. LOUIS, Mo. , Sept. 16, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that Kimberly Peery has been appointed Stereotaxis Chief Financial Officer, effective October 1, 2019
View HTML
Toggle Summary Stereotaxis Announces Uplisting to NYSE American
ST. LOUIS , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that its common stock has been approved for listing on the NYSE American.
View HTML
Toggle Summary Stereotaxis Reports 2019 Second Quarter Financial Results
ST. LOUIS , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2019 . In a separate press release issued concurrently with
View HTML
Toggle Summary Stereotaxis Announces $25 Million Private Placement
ST. LOUIS , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with select institutional investors for a $25 million
View HTML
Toggle Summary Stereotaxis to Report Second Quarter 2019 Financial Results on August 8, 2019
ST. LOUIS , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2019 second quarter ended June 30, 2019 on Thursday, August 8,
View HTML
Toggle Summary Society for Cardiac Robotic Navigation to Showcase Stereotaxis Clinical Value & Technology
ST. LOUIS , July 31, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will participate in the Society for Cardiac Robotic Navigation’s 4th Annual Meeting , which will take place
View HTML
Toggle Summary Stereotaxis Announces the First Graduating Class of the Robotic Electrophysiology Fellows Program
ST. LOUIS , June 18, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the first graduating class from its Robotic Electrophysiology Fellows Program.
View HTML
Toggle Summary Stereotaxis to Present at 9th Annual LD Micro Invitational
ST. LOUIS , May 29, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel , Chairman and Chief Executive Officer, is scheduled to present at the 9th Annual LD Micro
View HTML
Toggle Summary Stereotaxis Announces Next Generation Robotic Magnetic Navigation System and Imaging System
Innovative robotic surgery system, Stereotaxis Genesis™ RMN, enriches robotic magnetic navigation with increased efficiency, reduced size, and enhanced lab experience Genesis RMN System to be available in combination with Stereotaxis Imaging Model S, a next-generation x-ray system offered as part
View HTML
Toggle Summary Stereotaxis and Osypka Enter Strategic Collaboration to Advance Robotic Catheter Technology
  Development of next generation robotically-navigated magnetic ablation catheter fully owned by Stereotaxis   Catheter designed to enhance patient care, improve therapy delivery, simplify catheter navigation, and strengthen commitment to open ecosystem   Entered into additional business agreements
View HTML
Toggle Summary Stereotaxis Reports 2019 First Quarter Financial & Operational Results
ST. LOUIS , May 09, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2019 . In separate press releases issued concurrently with
View HTML
Toggle Summary Stereotaxis to Showcase Innovation and Technology at Heart Rhythm 2019 and Report First Quarter 2019 Financial Results on May 8-9, 2019
Innovation Update Presentation on the Evening of May 8 at Heart Rhythm Society Innovation Update Press Releases and First Quarter Financial Release Issued Prior to the Market Open on May 9 First Quarter Investor Conference Call on May 9 at 9:00 a.m. Eastern Time ST.
View HTML
Toggle Summary Stereotaxis to Highlight Latest Techniques for Performing Robotic Ablations at European Heart Rhythm Association Annual Congress March 17-19
ST. LOUIS , March 15, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it will be attending the European Heart Rhythm Association (EHRA) Annual Congress from March 17-19 in
View HTML
Toggle Summary Stereotaxis and Acutus Medical Combine Robotic Precision and High-Resolution Imaging to Treat Arrhythmias in First Integrated Procedures
First patients successfully treated with robust integration of technologies Integrated technologies now commercially available ST. LOUIS and CARLSBAD, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- Stereotaxis  (OTCQX: STXS) and Acutus Medical today announced the first patients have been successfully
View HTML
Toggle Summary Stereotaxis Reports 2018 Full Year Financial Results
Record high annual recurring revenue of $27.8 million ; 3% annual growth Positive annual net income for the first time in Company history despite significantly increased R&D investments Innovation initiatives to be showcased in May at Heart Rhythm Society meeting Strong financial position to reach
View HTML
Toggle Summary Stereotaxis to Report Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019
ST. LOUIS , March 04, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 fourth quarter and full year ended December 31, 2018 on
View HTML
Toggle Summary Stereotaxis to Participate in BTIG Healthcare Investor Conference
ST. LOUIS , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel , Chairman and Chief Executive Officer, is scheduled to participate in the BTIG Healthcare
View HTML
Toggle Summary Stereotaxis Announces Partnership with Kansas City Heart Rhythm Institute to Bring New Treatment to Arrhythmia Patients
ST. LOUIS , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias announced today a partnership with Kansas City Heart Rhythm Institute to bring new and cutting-edge treatments to arrhythmia
View HTML
© Copyright Stereotaxis 2019